Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-608 in Moderate-to-Severe Plaque Psoriasis
NCT05536726Phase 3Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of 608 in plaque psoriasis, sponsored by 3S Guojian Pharmaceutical. Started Jan 2023; status: completed.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05536726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536726.